Skip to main content

An update on Weight Loss Medication, Tirzepatide 23rd June 2025

An Update on Weight Loss Medication, Tirzepatide 23rd June 2025

NHS England and NICE have approved the use of Tirzepatide, which you may also know as Mounjaro ® from primary care from 23rd June 2025. However, in the first two years entry criteria has been set by NHS England to a very small number of people. This is to allow safe entry of this repurposed medicine into the health system.

Please only contact us if you are eligible. The eligibility criteria is below:

  • BMI or 40 or higher

AND AT LEAST 4 OF THE BELOW CONDITIONS

  1. Hypertension
  2. Dyslipidaemia
  3. Obstructive sleep apnoea
  4. Atherosclerotic Cardiovascular Disease (ASCVD)
  5. Type 2 diabetes mellitus

Please note that an appointment with a prescriber is required before starting this medication. Meeting the eligibility criteria does not guarantee that the prescriber will deem it appropriate to prescribe.